OCULAR ADVERSE EVENTS ASSOCIATED WITH PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IMMUNOTHERAPY

被引：0
|
作者：
Young, LeAnne [1 ]
Finnigan, Shanda [2 ]
Streicher, Howard [2 ]
Chen, Helen [2 ]
Murray, James [2 ]
Sen, H. Nida [1 ]
Sharon, Elad [2 ]
机构：
[1] NEI, Cleveland, OH USA
[2] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
644
引用
收藏
页码：A386 / A387
页数：2
相关论文
共 50 条
  • [21] Programmed Cell Death-1/ Ligand-1 PET Imaging A Novel Tool to Optimize Immunotherapy?
    Verhoeff, Sarah R.
    van den Heuvel, Michel M.
    van Herpen, Carla M. L.
    Piet, Berber
    Aarntzen, Erik H. J. G.
    Heskamp, Sandra
    PET CLINICS, 2020, 15 (01) : 35 - 43
  • [22] Clinical significance and therapeutic potential of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer
    Grimm, M.
    Gasser, M.
    Koenigshausen, M.
    Stein, C.
    Lutz, J.
    Krol, S.
    Thiede, A.
    Heemann, U.
    Waaga-Gasser, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Prognostic value of programmed death ligand-1 and programmed death-1 expression in patients with upper tract urothelial carcinoma
    Campedel, Luca
    Comperat, Eva
    Cancel-Tassin, Geraldine
    Varinot, Justine
    Pfister, Christian
    Delcourt, Clara
    Gobet, Francoise
    Roumiguie, Mathieu
    Patard, Pierre-Marie
    Daniel, Gwendoline
    Bigot, Pierre
    Carrouget, Julie
    Eymerit, Caroline
    Larre, Stephane
    Leon, Priscilla
    Durlach, Anne
    Ruffion, Alain
    de Mazancourt, Emilien Seizilles
    Decaussin-Petrucci, Myriam
    Bessede, Thomas
    Lebacle, Cedric
    Ferlicot, Sophie
    Robert, Gregoire
    Vuong, Nam-Son
    Philip, Magali
    Crouzet, Sebastien
    Matillon, Xavier
    Mege-Lechevallier, Florence
    Lang, Herve
    Mouracade, Pascal
    Lindner, Veronique
    Gougis, Paul
    Cussenot, Olivier
    Roupret, Morgan
    Seisen, Thomas
    BJU INTERNATIONAL, 2023, 132 (05) : 581 - 590
  • [24] Correction to: Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review
    Caleb J. Smith
    Yahya Almodallal
    Aminah Jatoi
    Current Oncology Reports, 2021, 23
  • [25] Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis
    Chakravarti, Nitin
    Prieto, Victor G.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (06) : 743 - 751
  • [26] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
    Cheah, Chan Yoon
    Fowler, Nathan H.
    Neelapu, Sattva S.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 384 - 391
  • [27] Analysis of the association between adverse events and outcome in patients receiving a programmed death protein-1 or programmed death ligand-1 antibody
    Garcia-Aranda, Marilina
    Redondo, Maximino
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [28] Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis
    Yanaba, Koichi
    Hayashi, Mitsuha
    Yoshihara, Yuki
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2016, 43 (08): : 954 - 957
  • [29] Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
    Wang, Yiming
    Ma, Rena
    Liu, Fang
    Lee, Seul A.
    Zhang, Li
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [30] Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
    Zhou, Tingting
    Xu, Di
    Tang, Bufu
    Ren, Yanling
    Han, Yiru
    Liang, Gege
    Wang, Jing
    Wang, Ling
    ANTI-CANCER DRUGS, 2018, 29 (09) : 904 - 910
12345